Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with
solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic
acid (DNA) damage repair genes that have spread to other places in the body (advanced) and
have come back (relapsed) or do not respond to treatment (refractory). Olaparib is an
inhibitor of PARP, an enzyme that helps repair DNA when it becomes damaged. Blocking PARP may
help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors
are a type of targeted therapy.
I. To determine the objective response rate (ORR; complete response + partial response) in
pediatric patients treated with olaparib with advanced solid tumors (including central
nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor
activating genetic alterations in the deleterious genetic alterations in the DNA damage
repair (DDR) pathway.
I. To estimate the progression free survival in pediatric patients treated with olaparib with
advanced solid tumors including non-Hodgkin lymphomas, CNS tumors, and histiocytosis that
harbor deleterious genetic alterations in the DDR pathway.
II. To obtain information about the tolerability of olaparib in children and adolescents with
relapsed or refractory cancer.
III. To provide preliminary estimates of the pharmacokinetics of olaparib in children and
adolescents with relapsed or refractory cancer.
I. To explore approaches to profiling changes in tumor genomics over time through the
evaluation of circulating tumor DNA.
Patients receive olaparib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28
days for 2 years in the absence of disease progression or unacceptable toxicity.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.